Prostate Cancer Daily

May 19, 2026

Videos

Peer-to-Peer Clinical Conversations

EMBARK Trial Reports Overall Survival Benefit for Enzalutamide with ADT in High-Risk Non-Metastatic Prostate Cancer - Stephen Freedland

Stephen Freedland

Zachary Klaassen speaks with Stephen Freedland about EMBARK trial overall survival data.

View

Overall Survival Results from the TALAPRO-2 Trial in mCRPC Patients - Neeraj Agarwal

Neeraj Agarwal

Oliver Sartor speaks with Neeraj Agarwal about the overall survival results from the TALAPRO-2 trial, which led to approval of talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer.

View

Beyond the Abstracts

Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review - Beyond the Abstract

A Sensitive and Specific Non-Invasive Urine Biomarker Panel for Prostate Cancer Detection - Beyond the Abstract

Conference Coverage

AUA 2026: Development and Clinical Implementation of a Simple Radium-223 Non-Completion Risk Calculator for Bone-Metastatic Castration-Resistant Prostate Cancer

AUA 2026: Neoadjuvant Apalutamide Therapy Enhances Potency Preservation Following Radical Prostatectomy by Downstaging the Disease in Men with High-Risk Prostate Cancer: Results of a Randomized Three-Arm Phase II Trial

AUA 2026: Uptake of Doublet and Triplet Therapy for Men with De Novo Metastatic Castration Sensitive Prostate Cancer. Population-Based Study

APCCC 2026: How to Select Patients with mHSPC for ADT plus an ARPI plus a Targeted Therapy (PARP or AKT Inhibition)?

APCCC 2026: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Results After 5 Rounds of PSA Screening (The IMPACT Study)

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer.

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.

Germline polygenic score for prostate cancer aggressiveness.

Community voices, strategies to improve understanding, and access to prostate cancer genomic testing.

Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer.

Intrafraction Motion Mitigation by Rectal Spacers in Prostate SBRT: Balloon, Hydrogel, and No-Spacer Comparison.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login